Bristol-Myers Squibb is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 4 active Congressional signals mentioning Bristol-Myers Squibb, including 4 bills. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
HR8032 (FAIC Act) is an early-stage bill requiring separate Medicare Part B payment for qualifying cancer drugs, eliminating a hospital incentive to avoid expensive branded oncology therapies. The bill protects $50B+ in oncology drug revenue for major pharma companies but faces a long legislative path through two committees. Current stock prices for affected tickers are near the bottom of their 52-week ranges, suggesting market pessimism is already priced in, creating asymmetric upside if the bill advances.
→ Hospitals must receive separate, pass-through payment at ASP for qualifying cancer drugs, removing the financial incentive to avoid high-cost branded oncology therapies since the hospital no longer absorbs the drug cost within a bundled rate.
HR1492 retroactively extends the Medicare price negotiation safe harbor for small-molecule drugs from 7 to 11 years, matching biologics. This shields billions in revenue for major pharma companies, particularly pure-play small-molecule firms like Vertex and large players with top-selling Part D drugs like Pfizer, Bristol-Myers Squibb, and Gilead. The bill is early-stage with 67 cosponsors and a Republican sponsor, giving it moderate momentum.
→ Bristol-Myers Squibb's small-molecule drugs (e.g., Eliquis, Revlimid) are shielded from negotiation for an additional 4 years. Eliquis is co-marketed with Pfizer and is the largest single Part D drug by spending (~$12B annual US sales).
HR6319 is an early-stage bill that establishes a Lung Cancer Task Force within NIH to study research disparities, funding levels, and screenings. It authorizes no funding and creates no direct revenue or cost impact on any publicly traded company. No market action is justified at this stage.
HR4101 (Cancer Drug Parity Act) was introduced in the House and referred to committee in June 2025. It mandates equal cost-sharing for oral and intravenous anticancer drugs in group health plans. At this early legislative stage with no committee action or companion bill, the market impact is negligible. Targeted pharmaceutical companies with oral oncology portfolios could benefit if the bill advances, but passage is highly uncertain.
→ Lower patient cost-sharing for oral anticancer drugs increases patient adherence and prescription fill rates, expanding the addressable patient population for oral oncology products.